| Part I:Hemochromatosis Protein Polymorphisms and Breast Cancer-A Meta-AnalysisObjective:Several studies have focused on the association between hemochromatosis (HFE) gene polymorphisms and susceptibility to breast cancer; however, results is of conflict. Whether the variations in the HFE gene increase breast cancer risk is still undetermined. We performed a meta-analysis to systematically investigate the potential association.Methods:Studies that had been published through 30th July,2011 were identified by searching Pubmed/MEDLINE and Embase databases complemented with screening the references of the retrieved studies. All analyses were performed with the use of RevMan statistical software version 5.1. For all alleles and genotypes, odds ratios (OR) were pooled with 95% confidence intervals (CIs). Statistical heterogeneity of the data was quantitated using the I2 statistic and the x2-based Cochran's Q statistic together.Results:A total of 9 articles were included for the current analyses. Two studies are corhot studies, others are case-control. The subjects were all Caucasians. We performed the meta-analysis of 8 studies with 1737 cases and 18456 controls to explore the association between C282Y polymorphism and breast cancer:Y allele did not increase the risk for breast cancer (OR:1.01,95% CI 0.73-1.38)compared to C allele; In genotype contrast models, only C282Y homozygosity genotype increased the risk for breast cancer compared to control groups. We performed the meta-analysis of 6 studies with 960 cases and 1731 controls to explore the association between H63D polymorphism and breast cancer:H63D allele mutation not increased the risk for breast cancer; In genotypes contrast models, H63D homozygosity,H63D heterozygotes and H63D homozygosity plus heterozygotes also did not increase the risk for breast cancer (OR:0.97,95% CI 0.55-1.72; OR:1.10,95% CI 0.77-1.57; OR:1.10,95% CI 0.81-1.51, respectively)Conclusion:Our systematic review supported an association between the C282Y mutation of HFE and breast cancer, and did not suggest that H63D increased the risk of breast cancer. Part II:Hemochromatosis Protein Polymorphisms and Hepatocelluar carcinoma-A Meta-AnalysisObjective:Some research have focused on the relationship between HFE gene polymorphisms and hepatocelluar carcinoma; however, results is inconsistent. Whether the mutations in the HFE gene increase hepatocelluar carcinoma risk is still undetermined. We conducted a meta-analysis to systematically explore the potential association.Methods:Studies that had been published through 26th March 2011 were identified by searching Pubmed/MEDLINE and Embase databases complemented with screening the references of the retrieved studies. All analyses were performed with the use of RevMan statistical software version 5.1. For all alleles and genotypes, OR were pooled with 95% CIs. Statistical heterogeneity of the data was quantitated using the I2 statistic and the x2-based Cochran's Q statistic together.Results:A total of 13 articles were included for the current analyses. One studie is corhot studies, others are case-control. The subjects were all Caucasians. We performed the meta-analysis of 13 studies with 1212 cases and 4511 controls to investigate the relationship between C282Y polymorphism and hepatocelluar carcinorma:Y allele increased the risk for hepatocelluar carcinoma (OR:1.58,95% CI 1.10-2.27) compared to C allele; In genotype contrast models, C282Y homozygosity,C282Y heterozygotes and C282Y homozygosity plus heterozygotes also increased the risk for colorectal cancer (OR:5.10, 95% CI 2.58-10.09; OR:1.28,95% CI 1.01-1.63; OR:1.48,95% CI 1.18-1.85, respectively. We conducted the meta-analysis of 12 studies with 1068 cases and 3030 controls to investigate the association between H63D mutations and liver cancer:H63D allele mutation not increased the risk for colorectal cancer (OR:1.12,95% CI 0.89-1.47); In genotypes contrast models, H63D homozygosity,H63D heterozygotes and H63D homozygosity plus heterozygotes also did not increase the risk for breast cancer (OR:1.04,95% CI 0.63-1.71; OR:1.18,95% CI 1.00-1.48; OR:1.19,95% CI 0.99-1.37, respectively)Conclusion:Our systematic review supported an association between the C282Y of HFE mutation and hepatocelluar carcinoma, did not suggest that H63D mutation increased the risk for hepatocelluarcarcinoma.PartⅢ:Hemochromatosis Protein Polymorphisms and Colorectal Cancer-A Meta-AnalysisObjective:Several studies have focused on the association between hemochromatosis (HFE) gene mutations and risk to colorectal cancer; however, results is of conflict. Whether the HFE gene mutations increase colorectal cancer risk is still unclear. We performed a meta-analysis to systematically investigate the potential association.Methods:Studies that had been published through 30th April,2011 were identified by searching Pubmed/MEDLINE and Embase databases complemented with screening the references of the retrieved studies. All analyses were performed with the use of RevMan statistical software version 5.1. For all alleles and genotypes, OR were pooled with 95% CIs. Statistical heterogeneity of the data was quantitated using the I2 statistic and theχ2-based Cochran's Q statistic together.Results:A total of 10 articles with 11 datas were included for the current analyses. Two studies are corhot studies, others are case-control. The subjects were all Caucasians. We performed the meta-analysis of 11 studies with 3367 cases and 40269 controls to explore the association between C282Y polymorphism and colorectal cancer:Y allele did not increase the risk for colorectal cancer (OR:0.98,95% CI 0.87-1.10) compared to C allele; In genotype contrast models, C282Y homozygosity,C282Y heterozygotes and C282Y homozygosity plus heterozygotes also did not increase the risk for colorectal cancer (OR: 1.21,95% CI 0.74-1.97; OR:1.01,95% CI 0.89-1.16; OR:1.02,95% CI 0.89-1.16, respectively. We performed the meta-analysis of 7 studies with 2345 cases and 11333 controls to explore the association between H63D polymorphism and colorectal cancer: H63D allele mutation not increased the risk for colorectal cancer (OR:1.09,95% CI 0.98-1.23); In genotypes contrast models, H63D homozygosity,H63D heterozygotes and H63D homozygosity plus heterozygotes also did not increase the risk for breast cancer (OR: 1.19,95% CI 0.83-1.71; OR:1.08,95% CI 0.95-1.24; OR:1.09,95% CI 0.96-1.24, respectively)Conclusion:Our systematic review did not support an association between the C282Y and H63D of HFE mutation and colorectal cancer. |
PDF Full Text Request